SCHEMBL632084

SCHEMBL632084

c1cnc(NCc2cnc[nH]2)cn1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
HPGD P15428 4/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
KDM4E B2RXH2 5/20 0.49
ADRA2C P18825 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ADRA1A P35348 2/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1B P35368 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631939 0.76 NOS2 (0.54) MEN1KMT2ATAAR1ADRA2CADRA1A
SCHEMBL631927 0.73 TAAR1 (0.49) TAAR1ADRA2CADRA1AADRA1DADRA1B
SCHEMBL22792037 0.70 TAAR1 (0.45) ALDH1A1MEN1KMT2ATAAR1ADRA2C
SCHEMBL3952458 0.69 ALDH1A1 (0.77) ALDH1A1HPGDMEN1KMT2AKDM4E
SCHEMBL3953451 0.68 ALDH1A1 (1.00) ALDH1A1HPGDMEN1KMT2AKDM4E
SCHEMBL4901454 0.68 TAAR1 (1.00) TAAR1ADRA2CADRA1AADRA1DADRA1B
SCHEMBL633069 0.68 TAAR1 (0.54) TAAR1ADRA2CADRA1AADRA1DADRA1B
SCHEMBL10228056 0.68 TAAR1 (0.54) TAAR1ADRA2CADRA1AADRA1DADRA1B
SCHEMBL10226960 0.68 ADRA2C (0.52) TAAR1ADRA2CADRA1AADRA1DADRA1B
SCHEMBL1462344 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586617-B2 Aminomethyl-4-imidazoles HOFFMANN-LA ROCHE INC. (US) 2013-11-19 US disclosed
US-8586617-B2 Aminomethyl-4-imidazoles HOFFMANN-LA ROCHE INC. (US) 2013-11-19 US disclosed
EP-2076497-B1 AMINOMETHYL-4-IMIDAZOLES HOFFMANN LA ROCHE (CH) 2012-02-22 EP disclosed
EP-2076497-B1 AMINOMETHYL-4-IMIDAZOLES HOFFMANN LA ROCHE (CH) 2012-02-22 EP disclosed
EP-2076497-A1 AMINOMETHYL-4-IMIDAZOLES F. Hoffmann-Roche AG (CH) 2009-07-08 EP disclosed
US-20080119535-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-05-22 US disclosed
WO-2008046757-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed
WO-2008046757-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119535-A1 AMINOMETHYL-4-IMIDAZOLES INMT, HTR4, MC4R ALDH1A1 631/4885HPGD 3580/4885MEN1 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.